title: Ibandronate: A Review in Japanese Patients with Osteoporosis.
abstract: Once-monthly intravenous (IV) ibandronate (Bonviva(®)) 1 mg and once-monthly oral ibandronate 100 mg are approved in Japan for the treatment of osteoporosis. In two well-designed trials in Japanese patients with primary osteoporosis, IV ibandronate 1 mg once monthly was noninferior to oral risedronate 2.5 mg once daily in terms of the cumulative incidence of new or worsening vertebral fractures at 3 years (MOVER trial) and oral ibandronate 100 mg once monthly was noninferior to IV ibandronate 1 mg once monthly in terms of the increase from baseline in lumbar spine bone mineral density at 12 months (MOVEST trial). Once-monthly IV and oral ibandronate were generally well tolerated in patients with osteoporosis. In conclusion, once-monthly IV and oral ibandronate are useful options for the treatment of Japanese patients with osteoporosis.
authors.affiliation: Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Keating
mesh_terms: D061605:Administration, Intravenous; D000284:Administration, Oral; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D007564:Japan / Q000453:epidemiology; D008159:Lumbar Vertebrae; D010024:Osteoporosis / Q000188:drug therapy*; D000068296:Risedronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000517:prevention & control
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000068296:Risedronic Acid; D000077557:Ibandronic Acid